Repligen Conference: CEO touts differentiated bioprocessing portfolio; CFO targets 30% EBITDA margin

Key Points

• Portfolio and commercial momentum: CEO Olivier says about 80% of Repligen’s products are differentiated, spotlighting ATF and pre‑packed columns and pushing bundled “full‑solution” workflows to deepen penetration at large biopharma and CDMO customers.
• Ambitious margin targets and recent progress: CFO Jason is targeting ~30% EBITDA margin (and 25%+ EBIT) by 2030, noting a 240 basis‑point EBIT expansion in 2025 (ex‑M&A) and guidance for a further 150 basis‑point improvement in 2026 via pricing, volume leverage, manufacturing productivity and a “Fit for Growth” program.
• Near‑term visibility constrained by industry dynamics: management flags a specific gene‑therapy headwind embedded in 2026 guidance, continued muted CapEx, limited biologic FDA approvals hurting ecosystem confidence, though small‑biotech order intake has shown three quarters of improvement.

Repligen NASDAQ: RGEN executives outlined a strategy focused on portfolio breadth, innovation, and commercial execution during a recent discussion with Life Science Analyst Paul Knight. Chief Executive Officer Olivier said he has been with the company about two and a half years and has served as CEO for roughly a year and a half, adding that he is “more excited than ever” about the company’s positioning in bioprocessing.

Portfolio breadth and “differentiated” products

Olivier emphasized that innovation remains central to Repligen’s approach, describing an effort to help customers improve yields and reduce manufacturing costs. In response to a question about differentiation across the portfolio, he said roughly 80% of the company’s products are differentiated, driven by research and development aimed at solving unmet customer needs.

He highlighted two examples:

• ATF (a process intensification technology): Olivier said customers have asked for ways to “get more out of the same footprint,” and Repligen has continued to advance ATF through multiple generations.
• Pre-packed columns: He said customers increasingly value outsourced column packing expertise, citing industry talent challenges and the advantages of working with a supplier that has packed thousands of columns.

For the remaining portion of the portfolio where Repligen faces more direct competition—Olivier pointed to fluid management—he said the company aims to differentiate through service, lead times, and customer-centric support. He also referenced ongoing challenges in single-use technologies, including extractables, leachables, and leakages, as areas where stronger service can matter.

Commercial momentum: deeper penetration at large accounts and broader solutions

Olivier said Repligen’s visibility with large biopharma and CDMO customers has increased significantly compared with two and a half years ago. At that time, he said, major accounts knew the company for “maybe a couple” product lines. Today, he said those customers recognize Repligen as having one of the broadest bioprocessing portfolios in the industry.

He added that, over the last five years, the number of product lines sold into large accounts has increased by a factor of 2.5. Repligen is also working toward packaging multiple technologies into “full solution” offerings, with a goal of presenting more complete workflows rather than pitching products individually.

On the equipment side, Olivier said an expanded offering has increased Repligen’s participation in large requests for proposals. He cited downstream systems—such as ARTeSYN tangential flow filtration (TFF) and chromatography systems—as well as mixers, and said Repligen can cover “almost 80%” of the equipment needs when a company builds a new bioprocessing plant.

2025 performance drivers and product-line highlights

Discussing how results evolved through 2025, Olivier said the year underscored the value of a broad portfolio and a strong sales organization. He said the company encountered an unexpected headwind tied to a “new modality” and that filtration—described as Repligen’s biggest franchise—was affected most. At the same time, he said other franchises performed “much, much better” than expected.

Olivier pointed to two areas as standouts:

• Proteins: He said the company rebounded after losing two historical OEM customers in 2024 and returned to prior levels faster than he expected, while shifting toward a broader base of end customers.
• Analytics: He said the launch of the SoloVPE PLUS exceeded expectations, and noted that less than 10% of the installed base has been replaced so far, suggesting continued cycle benefits.

Margin targets and operating leverage plan

Chief Financial Officer Jason said the company’s long-term objective is approximately 30% EBITDA margin and roughly 25%+ EBIT margin by 2030. He said the path is expected to involve smaller margin steps over the next couple of years, with acceleration as scale grows and operating leverage improves.

Jason cited several levers, including value-based pricing, volume leverage, manufacturing productivity, and managing operating expense growth below top-line growth. He also described ongoing investment in a “Fit for Growth” journey to strengthen people, processes, and infrastructure, with the expectation that investment needs will moderate later in the decade.

He said Repligen delivered strong margin expansion in 2025, noting that excluding the impact of M&A, the company expanded EBIT margin by 240 basis points. For 2026, he said the company has guided to 150 basis points of EBIT margin expansion.

2026 assumptions: CapEx, small biotech, and FDA approvals

On 2026, Olivier said the company’s guidance is “very similar” to what Repligen had at the beginning of 2025, though he added it was developed independently and only later did management notice the similarity. He reiterated a framework of growing at least 5% faster than the market, but said 2026 includes a “+5 minus 2” impact related to a headwind from a specific gene therapy program.

He also discussed industry conditions affecting visibility:

• CapEx spending: Olivier said capital spending has not returned to desired levels, though Repligen’s hardware business was flat in 2025 versus 2024. He said management believes an improvement would be a “huge tailwind” once spending accelerates.
• Small biotech demand: He said Repligen has seen three consecutive quarters of improving order intake, aligning with improved funding levels late in the year.
• FDA approvals and policy: Olivier said there have been “almost no biologic drug” approvals so far this year and argued approvals are important to restore ecosystem confidence. He also referenced uncertainty around “Most-Favored-Nation” dynamics and how it may influence customer decisions, including onshoring.

Closing the discussion, Olivier said he remains optimistic about bioprocessing and expects “several years of very nice growth” ahead, while watching for improvements in FDA approvals and a clearer shift in customer investment decisions.

About Repligen NASDAQ: RGEN

Repligen Corporation NASDAQ: RGEN is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen's offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company's core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.